Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention

Takaaki Yamada, Nobuaki Egashira, Hiroyuki Watanabe, Kenichiro Nagata, Takahisa Yano, Toshiharu Nonaka, Ryozo Oishi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose The intravenous injection of vinorelbine often causes venous irritation such as erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the vinorelbineinduced venous irritation and to establish a suitable administration method of vinorelbine. Methods We analyzed the risk factor associated with venous irritation in 63 patients administered vinorelbine from April 2006 to September 2008. We subsequently changed the regimen of vinorelbine and examined the incidence of venous irritation in 24 patients administered vinorelbine from October 2008 to March 2010. Results A multivariate logistic regression analysis revealed that the dose of vinorelbine (≥40 mg) was a significant predictor for venous irritation (adjusted odds ratio=4.39; 95% confidence intervals, 1.33-14.49; p=0.015). Moreover, the grade of venous irritation in patients administered vinorelbine at the doses of ≥40 mg was significantly higher than that in patients administered vinorelbine at the doses of <40 mg (p=0.011). Based on this result, we altered the volume of normal saline for vinorelbine dissolution from 50 to 100 mL. After the change of regimen, the grade of venous irritation induce by vinorelbine was significantly decreased (p=0.034), although the incidence was not significantly changed (46.0% versus 33.3%). Conclusions The change of regimen of vinorelbine based on the analysis significantly decreased the grade of venous irritation. Pharmacists can contribute to the management for the vinorelbine-induced venous irritation.

Original languageEnglish
Pages (from-to)1549-1553
Number of pages5
JournalSupportive Care in Cancer
Volume20
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Pharmaceutical Preparations
vinorelbine
Phlebitis
Incidence
Erythema
Pharmacists
Intravenous Injections
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Pain
Injections

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention. / Yamada, Takaaki; Egashira, Nobuaki; Watanabe, Hiroyuki; Nagata, Kenichiro; Yano, Takahisa; Nonaka, Toshiharu; Oishi, Ryozo.

In: Supportive Care in Cancer, Vol. 20, No. 7, 07.2012, p. 1549-1553.

Research output: Contribution to journalArticle

Yamada, Takaaki ; Egashira, Nobuaki ; Watanabe, Hiroyuki ; Nagata, Kenichiro ; Yano, Takahisa ; Nonaka, Toshiharu ; Oishi, Ryozo. / Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention. In: Supportive Care in Cancer. 2012 ; Vol. 20, No. 7. pp. 1549-1553.
@article{3c3b529b743f4c27b1195abcae72b172,
title = "Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention",
abstract = "Purpose The intravenous injection of vinorelbine often causes venous irritation such as erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the vinorelbineinduced venous irritation and to establish a suitable administration method of vinorelbine. Methods We analyzed the risk factor associated with venous irritation in 63 patients administered vinorelbine from April 2006 to September 2008. We subsequently changed the regimen of vinorelbine and examined the incidence of venous irritation in 24 patients administered vinorelbine from October 2008 to March 2010. Results A multivariate logistic regression analysis revealed that the dose of vinorelbine (≥40 mg) was a significant predictor for venous irritation (adjusted odds ratio=4.39; 95{\%} confidence intervals, 1.33-14.49; p=0.015). Moreover, the grade of venous irritation in patients administered vinorelbine at the doses of ≥40 mg was significantly higher than that in patients administered vinorelbine at the doses of <40 mg (p=0.011). Based on this result, we altered the volume of normal saline for vinorelbine dissolution from 50 to 100 mL. After the change of regimen, the grade of venous irritation induce by vinorelbine was significantly decreased (p=0.034), although the incidence was not significantly changed (46.0{\%} versus 33.3{\%}). Conclusions The change of regimen of vinorelbine based on the analysis significantly decreased the grade of venous irritation. Pharmacists can contribute to the management for the vinorelbine-induced venous irritation.",
author = "Takaaki Yamada and Nobuaki Egashira and Hiroyuki Watanabe and Kenichiro Nagata and Takahisa Yano and Toshiharu Nonaka and Ryozo Oishi",
year = "2012",
month = "7",
doi = "10.1007/s00520-011-1244-3",
language = "English",
volume = "20",
pages = "1549--1553",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention

AU - Yamada, Takaaki

AU - Egashira, Nobuaki

AU - Watanabe, Hiroyuki

AU - Nagata, Kenichiro

AU - Yano, Takahisa

AU - Nonaka, Toshiharu

AU - Oishi, Ryozo

PY - 2012/7

Y1 - 2012/7

N2 - Purpose The intravenous injection of vinorelbine often causes venous irritation such as erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the vinorelbineinduced venous irritation and to establish a suitable administration method of vinorelbine. Methods We analyzed the risk factor associated with venous irritation in 63 patients administered vinorelbine from April 2006 to September 2008. We subsequently changed the regimen of vinorelbine and examined the incidence of venous irritation in 24 patients administered vinorelbine from October 2008 to March 2010. Results A multivariate logistic regression analysis revealed that the dose of vinorelbine (≥40 mg) was a significant predictor for venous irritation (adjusted odds ratio=4.39; 95% confidence intervals, 1.33-14.49; p=0.015). Moreover, the grade of venous irritation in patients administered vinorelbine at the doses of ≥40 mg was significantly higher than that in patients administered vinorelbine at the doses of <40 mg (p=0.011). Based on this result, we altered the volume of normal saline for vinorelbine dissolution from 50 to 100 mL. After the change of regimen, the grade of venous irritation induce by vinorelbine was significantly decreased (p=0.034), although the incidence was not significantly changed (46.0% versus 33.3%). Conclusions The change of regimen of vinorelbine based on the analysis significantly decreased the grade of venous irritation. Pharmacists can contribute to the management for the vinorelbine-induced venous irritation.

AB - Purpose The intravenous injection of vinorelbine often causes venous irritation such as erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the vinorelbineinduced venous irritation and to establish a suitable administration method of vinorelbine. Methods We analyzed the risk factor associated with venous irritation in 63 patients administered vinorelbine from April 2006 to September 2008. We subsequently changed the regimen of vinorelbine and examined the incidence of venous irritation in 24 patients administered vinorelbine from October 2008 to March 2010. Results A multivariate logistic regression analysis revealed that the dose of vinorelbine (≥40 mg) was a significant predictor for venous irritation (adjusted odds ratio=4.39; 95% confidence intervals, 1.33-14.49; p=0.015). Moreover, the grade of venous irritation in patients administered vinorelbine at the doses of ≥40 mg was significantly higher than that in patients administered vinorelbine at the doses of <40 mg (p=0.011). Based on this result, we altered the volume of normal saline for vinorelbine dissolution from 50 to 100 mL. After the change of regimen, the grade of venous irritation induce by vinorelbine was significantly decreased (p=0.034), although the incidence was not significantly changed (46.0% versus 33.3%). Conclusions The change of regimen of vinorelbine based on the analysis significantly decreased the grade of venous irritation. Pharmacists can contribute to the management for the vinorelbine-induced venous irritation.

UR - http://www.scopus.com/inward/record.url?scp=84863981646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863981646&partnerID=8YFLogxK

U2 - 10.1007/s00520-011-1244-3

DO - 10.1007/s00520-011-1244-3

M3 - Article

C2 - 21805382

AN - SCOPUS:84863981646

VL - 20

SP - 1549

EP - 1553

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 7

ER -